Research on gene therapy of neurons based on narcotic nanoparticles intervention in cerebral ischemia

Objective: To detect the efficiency of gene therapy of anaesthetic nanoparticle drug materials β-CD-PAMAM and β-CD-PAMAM/pEGFP-N3 in vitro to intervene in cerebral ischemic neurons, in preparation for further in vivo gene therapy. Methods: Standard non-viral vector polyamidoamine dendrimer PAMAM was used as a positive control group. Results: Cytotoxicity test: In the two types of cells, when N/P<10, all anaesthetic nanoparticle drug material carriers and their complexes showed low toxicity, and the cell survival rate was above 80% (P<0.05); When N/P>20, the cell survival rate of β-CDPAMAM and β-CD-PAMAM/pEGFP-N3 complex was higher than that of PAMAM and PAMAM/pEGFP-N3 complex (P < 0.05). Conclusion: The cytotoxicity and gene transfection efficiency of β-CD-PAMAM have been clarified, and it has been confirmed that β-CD-PAMAM can be used as a carrier for gene transfer in Hek293 and SH-SY5Y cells, and can further assist with gene therapy of cerebral ischemic neurons.